73097-02-6

Upstream product

• 64-17-5 ethanol 
• 77455-65-3 3-chloro-4-(dichloromethyl)-1-nitrobenzene 
• 121-86-8 2-chloro-4-nitrotoluene 
• 5568-33-2 2-chloro-4-nitrobenzaldehyde 
• 77455-54-0 2-chloro-4-nitrobenzal diacetate 
• 99-60-5 2-chloro-4-nitrobenzoic acid 

Downstream Products

• 89-40-7 4-nitrophthalimide 
• 1057076-51-3 ethyl 4-amino-2-chloro-5-iodobenzoate 
• 67345-78-2 2-chloro-4-nitrobenzohydrazide 
• 915390-03-3 ethyl 2-(morpholin-4-yl)-4-nitrobenzoate 
• 1346123-90-7 [4-amino-2-(morpholin-4-yl)phenyl][4-(2,4-dimethylphenyl)piperazin-1-yl]methanone 
• 1346123-91-8 [4-(2,4-dimethylphenyl)piperazin-1-yl][2-(morpholin-4-yl)-4-nitrophenyl]methanone 
• 94-09-7 p-aminoethylbenzoate 
• 119342-76-6 2,2'-dichloro-4,4'-azoxy-di-benzoic acid diethyl ester 
• 16017-69-9 ethyl-2-chloro-4-amino-benzoate 
• 119342-76-6 azoxy-4,4' dichloro-2,2' dibenzoate d'ethyle 

Relevant academic research and scientific papers

RETINOID COMPOUND AND PHARMACEUTICAL COMPOSITION

PROBLEM TO BE SOLVED: To provide a novel retinoid compound that is low in teratogenicity, and a pharmaceutical composition containing said retinoid compound. SOLUTION: Provided are a retinoid compound which is a compound represented by the following formula (1) or a salt thereof, and a pharmaceutical composition containing said retinoid compound. In the formula, R1 represents a halogen atom, and R2 and R3 each independently represent a silyl group. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES

The present invention relates to tetrazolyl-containing cyclopropanecarboxamides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds fo

Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure

The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic heteroaroma

MODULATORS OF MITOTIC KINASES

The invention relates to compounds of Formula (I), a prodrug, a polymorph, a tautomer, an enantiomer, a stereoisomer, a solvate, an N-oxide, or a pharmaceutically acceptable salt thereof: (formula should be inserted here) which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.

Guanidino substituted isoindolones as novel glycoprotein IIb-IIIa receptor antagonists

Design and synthesis of a novel potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonist based on isoindolone skeleton has been described. This scaffold has been derived from earlier reported pseudopeptides. Synthesis by a novel route has been achieved. Few molecules show very potent in vitro activity. Further identification of probable additional hydrogen bond donor site has been described.

Comparative Reactivity of Substituted 4-Nitrobenzylidene Dichlorides with Alkali

A comparative study of the reactions of substituted 4-nitrobenzylidene dichlorides ArCHCl2 (Ar = 3-Cl-4-NO2C6H3, 2-Cl-4-NO2C6H3, 4-NO2C6H4, 3,5-Me2-4-NO2C6H2, and 2-Me-4-NO2C6H3) with aqueous alcoholic alkali shows that chlorine substitution enhances the